Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)

Vera Gorbunova, J. Thaddeus Beck, Ralf Dieter Hofheinz, Pilar Garcia-Alfonso, Marina Nechaeva, Antonio Cubillo Gracian, Laszlo Mangel, Elena Elez Fernandez, Dustin A. Deming, Ramesh K. Ramanathan, Alison H. Torres, Danielle Sullivan, Yan Luo, Jordan D. Berlin

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Original languageEnglish (US)
Pages (from-to)429-430
Number of pages2
JournalBritish journal of cancer
Volume121
Issue number5
DOIs
StatePublished - Aug 27 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)'. Together they form a unique fingerprint.

Cite this